精神科药物处方者致幻剂的使用:对健康、抑郁、焦虑的影响,以及与使用模式、报告的危害和精神状态转变的关联。

Psychedelic medicine (New Rochelle, N.Y.) Pub Date : 2023-09-13 eCollection Date: 2023-09-01 DOI:10.1089/psymed.2023.0030
Zachary Herrmann, Adam W Levin, Steven P Cole, Sarah Slabaugh, Brian Barnett, Andrew Penn, Rakesh Jain, Charles Raison, Bhavya Rajanna, Saundra Jain
{"title":"精神科药物处方者致幻剂的使用:对健康、抑郁、焦虑的影响,以及与使用模式、报告的危害和精神状态转变的关联。","authors":"Zachary Herrmann, Adam W Levin, Steven P Cole, Sarah Slabaugh, Brian Barnett, Andrew Penn, Rakesh Jain, Charles Raison, Bhavya Rajanna, Saundra Jain","doi":"10.1089/psymed.2023.0030","DOIUrl":null,"url":null,"abstract":"<p><p>Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a large cross-sectional online survey consisting of participants with at least one lifetime psychedelic use sought to examine how use affects health care providers who treat psychiatric disorders with medications. In total, 228 respondents retrospectively completed measures of depression, anxiety, and well-being before and after psychedelic exposure. They also reported lifetime use, harms attributed to use, and preferred psychedelic agent. Psychedelic use was associated with improvements in depression, anxiety, and well-being. Reported suicidality decreased and resilience increased. A factor analysis suggested that a cluster of mystical, interpersonal, and personal items predicted improvement in depression, anxiety, well-being, suicidality, and resilience. Preferred psychedelic agent did not affect outcomes. Frequency of use was not associated with outcomes although differences in effect sizes were seen. Harm reported was consistent with the general population, with 13.2% (<i>n</i> = 30) reporting at least one harm. Pre-exposure alcohol use, aggressive impulses, and desire to die by suicide improved most often while marijuana use most often worsened or did not change. These results are consistent with clinical trials and naturalistic studies examining psychedelic use in the general population and suggest that health care providers who treat psychiatric disorders with medications may benefit from psychedelic use, although some harm was reported. Given the current mental health crisis among health care providers, further research is warranted to examine whether interventions utilizing psychedelics could improve well-being and effectiveness of health care providers while decreasing adverse mental health outcomes associated with working in health care. ClinicalTrials.gov (ID: NCT04040582).</p>","PeriodicalId":74590,"journal":{"name":"Psychedelic medicine (New Rochelle, N.Y.)","volume":"131 1","pages":"139-149"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661493/pdf/","citationCount":"0","resultStr":"{\"title\":\"Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.\",\"authors\":\"Zachary Herrmann, Adam W Levin, Steven P Cole, Sarah Slabaugh, Brian Barnett, Andrew Penn, Rakesh Jain, Charles Raison, Bhavya Rajanna, Saundra Jain\",\"doi\":\"10.1089/psymed.2023.0030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a large cross-sectional online survey consisting of participants with at least one lifetime psychedelic use sought to examine how use affects health care providers who treat psychiatric disorders with medications. In total, 228 respondents retrospectively completed measures of depression, anxiety, and well-being before and after psychedelic exposure. They also reported lifetime use, harms attributed to use, and preferred psychedelic agent. Psychedelic use was associated with improvements in depression, anxiety, and well-being. Reported suicidality decreased and resilience increased. A factor analysis suggested that a cluster of mystical, interpersonal, and personal items predicted improvement in depression, anxiety, well-being, suicidality, and resilience. Preferred psychedelic agent did not affect outcomes. Frequency of use was not associated with outcomes although differences in effect sizes were seen. Harm reported was consistent with the general population, with 13.2% (<i>n</i> = 30) reporting at least one harm. Pre-exposure alcohol use, aggressive impulses, and desire to die by suicide improved most often while marijuana use most often worsened or did not change. These results are consistent with clinical trials and naturalistic studies examining psychedelic use in the general population and suggest that health care providers who treat psychiatric disorders with medications may benefit from psychedelic use, although some harm was reported. Given the current mental health crisis among health care providers, further research is warranted to examine whether interventions utilizing psychedelics could improve well-being and effectiveness of health care providers while decreasing adverse mental health outcomes associated with working in health care. ClinicalTrials.gov (ID: NCT04040582).</p>\",\"PeriodicalId\":74590,\"journal\":{\"name\":\"Psychedelic medicine (New Rochelle, N.Y.)\",\"volume\":\"131 1\",\"pages\":\"139-149\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661493/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychedelic medicine (New Rochelle, N.Y.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/psymed.2023.0030\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychedelic medicine (New Rochelle, N.Y.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/psymed.2023.0030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

包括抑郁、焦虑、自杀和倦怠在内的心理健康问题在卫生保健提供者中很常见。适应力和幸福感被认为是防止这些事件发生的因素。迷幻化合物的临床试验和自然主义研究表明,在改善幸福感的同时,可以减少抑郁、焦虑和自杀。本研究对一项大型横断面在线调查进行了二次分析,该调查由至少一次使用致幻剂的参与者组成,旨在研究使用致幻剂如何影响用药物治疗精神疾病的卫生保健提供者。总共有228名受访者回顾性地完成了迷幻药暴露前后的抑郁、焦虑和幸福感测量。他们还报告了终身使用、使用造成的危害和首选致幻剂。迷幻药的使用与抑郁、焦虑和幸福感的改善有关。报告的自杀率下降,适应力增强。一项因素分析表明,一组神秘的、人际的和个人的物品可以预测抑郁、焦虑、幸福感、自杀倾向和恢复力的改善。首选致幻剂不影响结果。使用频率与结果无关,尽管效应大小存在差异。报告的危害与一般人群一致,有13.2% (n = 30)报告至少有一种危害。暴露前的酒精使用、攻击性冲动和自杀倾向最常得到改善,而大麻的使用最常恶化或没有改变。这些结果与临床试验和普通人群使用致幻剂的自然主义研究相一致,并表明用药物治疗精神疾病的卫生保健提供者可能从使用致幻剂中受益,尽管有一些危害的报道。鉴于目前卫生保健提供者的心理健康危机,有必要进一步研究使用致幻剂的干预措施是否可以改善卫生保健提供者的福祉和有效性,同时减少与卫生保健工作相关的不良心理健康结果。ClinicalTrials.gov (ID: NCT04040582)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.

Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a large cross-sectional online survey consisting of participants with at least one lifetime psychedelic use sought to examine how use affects health care providers who treat psychiatric disorders with medications. In total, 228 respondents retrospectively completed measures of depression, anxiety, and well-being before and after psychedelic exposure. They also reported lifetime use, harms attributed to use, and preferred psychedelic agent. Psychedelic use was associated with improvements in depression, anxiety, and well-being. Reported suicidality decreased and resilience increased. A factor analysis suggested that a cluster of mystical, interpersonal, and personal items predicted improvement in depression, anxiety, well-being, suicidality, and resilience. Preferred psychedelic agent did not affect outcomes. Frequency of use was not associated with outcomes although differences in effect sizes were seen. Harm reported was consistent with the general population, with 13.2% (n = 30) reporting at least one harm. Pre-exposure alcohol use, aggressive impulses, and desire to die by suicide improved most often while marijuana use most often worsened or did not change. These results are consistent with clinical trials and naturalistic studies examining psychedelic use in the general population and suggest that health care providers who treat psychiatric disorders with medications may benefit from psychedelic use, although some harm was reported. Given the current mental health crisis among health care providers, further research is warranted to examine whether interventions utilizing psychedelics could improve well-being and effectiveness of health care providers while decreasing adverse mental health outcomes associated with working in health care. ClinicalTrials.gov (ID: NCT04040582).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信